These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 23456099)

  • 21. Microperimetric changes after photodynamic therapy for central serous chorioretinopathy.
    Senturk F; Karacorlu M; Ozdemir H; Karacorlu SA; Uysal O
    Am J Ophthalmol; 2011 Feb; 151(2):303-9.e1. PubMed ID: 21168824
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Collaborative retrospective macula society study of photodynamic therapy for chronic central serous chorioretinopathy.
    Lim JI; Glassman AR; Aiello LP; Chakravarthy U; Flaxel CJ; Spaide RF;
    Ophthalmology; 2014 May; 121(5):1073-8. PubMed ID: 24439758
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparing effects of photodynamic therapy in central serous chorioretinopathy: full-dose versus half-dose versus half-dose-half-fluence.
    Park W; Kim M; Kim RY; Park YH
    Graefes Arch Clin Exp Ophthalmol; 2019 Oct; 257(10):2155-2161. PubMed ID: 31367848
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Threshold thickness of foveal outer nuclear layer associated with outcomes of photodynamic therapy in central serous chorioretinopathy.
    Yu J; Ye X; Li L; Jiang C; Chang Q; Xu G
    Eye (Lond); 2022 Oct; 36(10):1884-1889. PubMed ID: 34480115
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Observation on long-term efficacy of half-dose photodynamic therapy with chronic central serous chorioretinopathy using optical coherence tomography].
    Liu Y; Li L; Xu G; Wang W
    Zhonghua Yan Ke Za Zhi; 2016 May; 52(5):328-34. PubMed ID: 27220704
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic factors associated with treatment response to reduced-fluence photodynamic therapy for chronic central serous chorioretinopathy.
    Hayashida M; Miki A; Nakai S; Matsumiya W; Imai H; Kusuhara S; Honda S; Nakamura M
    Mol Vis; 2020; 26():505-509. PubMed ID: 32774081
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of visual and anatomical outcomes of half-fluence and half-dose photodynamic therapy in eyes with chronic central serous chorioretinopathy.
    Kim YK; Ryoo NK; Woo SJ; Park KH
    Graefes Arch Clin Exp Ophthalmol; 2015 Dec; 253(12):2063-73. PubMed ID: 25616728
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimal fluence rate of photodynamic therapy for chronic central serous chorioretinopathy.
    Park DG; Jeong S; Noh D; Sagong M
    Br J Ophthalmol; 2021 Jun; 105(6):844-849. PubMed ID: 32727733
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation between redefined optical coherence tomography parameters and best-corrected visual acuity in non-resolving central serous chorioretinopathy treated with half-dose photodynamic therapy.
    van Rijssen TJ; Mohabati D; Dijkman G; Theelen T; de Jong EK; van Dijk EHC; Boon CJF
    PLoS One; 2018; 13(8):e0202549. PubMed ID: 30142176
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improvement in multifocal electroretinography after half-dose verteporfin photodynamic therapy for central serous chorioretinopathy: a randomized placebo-controlled trial.
    Wu ZH; Lai RY; Yip YW; Chan WM; Lam DS; Lai TY
    Retina; 2011; 31(7):1378-86. PubMed ID: 21836413
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlation of integrity of cone outer segment tips line with retinal sensitivity after half-dose photodynamic therapy for chronic central serous chorioretinopathy.
    Fujita K; Shinoda K; Imamura Y; Matsumoto CS; Mizutani Y; Mizota A; Yuzawa M
    Am J Ophthalmol; 2012 Sep; 154(3):579-85. PubMed ID: 22818904
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of half-fluence photodynamic therapy depending on the degree of choroidal hyperpermeability in chronic central serous chorioretinopathy.
    Lim SH; Chang W; Sagong M
    Eye (Lond); 2013 Mar; 27(3):353-62. PubMed ID: 23449515
    [TBL] [Abstract][Full Text] [Related]  

  • 33. One-year results of half-dose versus one-third-dose photodynamic therapy in chronic or recurrent central serous chorioretinopathy.
    Pichai J; Vanchalerm B; Mansing R
    BMC Ophthalmol; 2021 Jan; 21(1):30. PubMed ID: 33430812
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aniseikonia after reduced-fluence photodynamic therapy in patients with central serous chorioretinopathy.
    Chubachi-Kamimura A; Miki A; Hayashida-Hirano M; Kishimoto-Kishi M; Okuda M; Matsumiya W; Imai H; Kusuhara S; Nakamura M
    Sci Rep; 2023 Oct; 13(1):17133. PubMed ID: 37816824
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term efficacy of half-dose photodynamic therapy on chronic central serous chorioretinopathy.
    Tseng CC; Chen SN
    Br J Ophthalmol; 2015 Aug; 99(8):1070-7. PubMed ID: 25680621
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison between the outcomes of fluorescein angiography-guided and indocyanine green angiography-guided half-time photodynamic therapy for central serous chorioretinopathy.
    Hayashida M; Miki A; Honda S; Nakamura M
    Photodiagnosis Photodyn Ther; 2020 Sep; 31():101955. PubMed ID: 32818640
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Half-dose vs one-third-dose photodynamic therapy for chronic central serous chorioretinopathy.
    Uetani R; Ito Y; Oiwa K; Ishikawa K; Terasaki H
    Eye (Lond); 2012 May; 26(5):640-9. PubMed ID: 22573069
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic factors related to photodynamic therapy for central serous chorioretinopathy.
    Moon JW; Yu HG; Kim TW; Kim HC; Chung H
    Graefes Arch Clin Exp Ophthalmol; 2009 Oct; 247(10):1315-23. PubMed ID: 19421764
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term results of focal laser photocoagulation and photodynamic therapy for the treatment of central serous chorioretinopathy.
    Shin YI; Kim KM; Lee MW; Kim JY; Jo YJ
    Jpn J Ophthalmol; 2020 Jan; 64(1):28-36. PubMed ID: 31863228
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the efficacy and safety between subthreshold micropulse laser, standard-fluence and low-fluence photodynamic therapy for chronic central serous chorioretinopathy.
    Altinel MG; Kanra AY; Totuk OMG; Ardagil A; Turkmen OF
    J Fr Ophtalmol; 2021 Apr; 44(4):499-508. PubMed ID: 33642060
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.